Neoantigen-specific ITC prediction
tumors, Neoantigens
TUMORS, SOMATIC MUTATIONS
Neoantigens were classified into immune clearance neoantigens and novel neoantigens according to the corresponding unique somatic mutations identified in pretreatment and post-treatment tumors. Neoantigens derived from somatic mutations that remained persistent during anti-PD-L1 treatment were defined as immune persistence neoantigens. ITCs specifically binding to the three types of neoantigen (neoantigen-specific ITCs) were inferred by pMTnet (v.1.0.0), which predicted the affinity between TCRs and peptide–MHC complex.